▪ Abstract Adenosine and its receptors have been the topic of many recent reviews (–).
These reviews provide a good summary of much of the relevant literature—including the …

The molecular basis for the known intramembrane receptor/receptor interactions among G
protein-coupled receptors was postulated to be heteromerization based on receptor subtype …

Recently evidence has been presented that adenosine A2A and dopamine D2 receptors
form functional heteromeric receptor complexes as demonstrated in human neuroblastoma …

In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A2A
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …

Activation of adenosine A2A receptors (A2AR) has been shown to antagonize the function of
D2 dopaminergic regulation of striatal γ‐aminobutyric acid (GABA)‐ergic output and, thus …

Abstract Kyowa Hakko Kirin is developing istradefylline, a selective adenosine A 2A receptor
antagonist, for the once-daily oral treatment of Parkinson's disease (PD). Adenosine A 2A …

Adenosine A2A receptors are abundant in the caudate‐putamen and involved in the motor
control in several species. In MPTP‐treated monkeys, A2A receptor‐blockade with an …

Parkinson′ s disease (PD) is a progressive extrapyramidal motor disorder. Pathologically,
this disease is characterized by the selective dopaminergic (DAergic) neuronal …

The objectives of this study were to evaluate the efficacy of istradefylline at an oral dose of
20 mg or 40 mg once daily for 12 weeks in Parkinson's disease (PD) patients with motor …

The A2AR is largely coexpressed with D2Rs and enkephalin mRNA in the striatum where it
modulates dopaminergic activity. Activation of the A2AR antagonizes D2R-mediated …